Modification of a tumor antigen determinant to improve peptide/MHC stability is associated with increased immunogenicity and cross-priming a larger fraction of CD8+ T cells.

PubWeight™: 0.83‹?›

🔗 View Article (PMC 3536056)

Published in J Immunol on November 21, 2012

Authors

Alan M Watson1, Lawrence M Mylin, Megan M Thompson, Todd D Schell

Author Affiliations

1: Department of Microbiology and Immunology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, USA.

Articles cited by this

T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature (2004) 11.14

Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med (1995) 9.79

Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature (1986) 9.73

Naive CD4(+) T cell frequency varies for different epitopes and predicts repertoire diversity and response magnitude. Immunity (2007) 9.26

Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science (1994) 6.73

gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24

T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation. Nat Immunol (2008) 4.52

The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37

Endogenous naive CD8+ T cell precursor frequency regulates primary and memory responses to infection. Immunity (2008) 4.25

T cells compete for access to antigen-bearing antigen-presenting cells. J Exp Med (2000) 4.16

Continuous T cell receptor signaling required for synapse maintenance and full effector potential. Nat Immunol (2003) 3.88

Host resistance directed selectively against H-2-deficient lymphoma variants. Analysis of the mechanism. J Exp Med (1985) 3.86

Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat Immunol (2005) 3.23

Enhanced dendritic cell antigen capture via toll-like receptor-induced actin remodeling. Science (2004) 3.08

Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol (2008) 2.25

Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24

Structural and kinetic basis for heightened immunogenicity of T cell vaccines. J Exp Med (2005) 2.22

Enhanced antigen-specific antitumor immunity with altered peptide ligands that stabilize the MHC-peptide-TCR complex. Immunity (2000) 2.13

Immunogenicity of peptides bound to MHC class I molecules depends on the MHC-peptide complex stability. J Immunol (1996) 2.11

A quantitative analysis of the variables affecting the repertoire of T cell specificities recognized after vaccinia virus infection. J Immunol (2007) 2.00

Primary CTL response magnitude in mice is determined by the extent of naive T cell recruitment and subsequent clonal expansion. J Clin Invest (2010) 1.92

Heteroclitic immunization induces tumor immunity. J Exp Med (1998) 1.92

The kinetic stability of MHC class II:peptide complexes is a key parameter that dictates immunodominance. Immunity (2005) 1.88

Tapasin enhances MHC class I peptide presentation according to peptide half-life. Proc Natl Acad Sci U S A (2004) 1.49

CD8 T cell competition for dendritic cells in vivo is an early event in activation. Proc Natl Acad Sci U S A (2006) 1.46

Determination of structural principles underlying three different modes of lymphocytic choriomeningitis virus escape from CTL recognition. J Immunol (2004) 1.46

Relationships among TCR ligand potency, thresholds for effector function elicitation, and the quality of early signaling events in human T cells. J Immunol (1998) 1.44

Diversity and recognition efficiency of T cell responses to cancer. PLoS Med (2004) 1.36

Quantitation of CD8(+) T-lymphocyte responses to multiple epitopes from simian virus 40 (SV40) large T antigen in C57BL/6 mice immunized with SV40, SV40 T-antigen-transformed cells, or vaccinia virus recombinants expressing full-length T antigen or epitope minigenes. J Virol (2000) 1.31

Poor immunogenicity of a self/tumor antigen derives from peptide-MHC-I instability and is independent of tolerance. J Clin Invest (2004) 1.30

Demonstration of multiple antigenic sites of the SV40 transplantation rejection antigen by using cytotoxic T lymphocyte clones. J Immunol (1983) 1.29

Reversal in the immunodominance hierarchy in secondary CD8+ T cell responses to influenza A virus: roles for cross-presentation and lysis-independent immunodomination. J Immunol (2004) 1.28

The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein-Barr virus nuclear antigen 4. J Exp Med (1996) 1.28

Redundancy of direct priming and cross-priming in tumor-specific CD8+ T cell responses. J Immunol (2001) 1.27

Increased immunogenicity of an anchor-modified tumor-associated antigen is due to the enhanced stability of the peptide/MHC complex: implications for vaccine design. J Immunol (2005) 1.27

Design of agonistic altered peptides for the robust induction of CTL directed towards H-2Db in complex with the melanoma-associated epitope gp100. Cancer Res (2009) 1.26

Peptide-MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity. Eur J Immunol (2012) 1.24

Immortalization of primary mouse embryo fibroblasts with SV40 virions, viral DNA, and a subgenomic DNA fragment in a quantitative assay. Virology (1984) 1.24

Cytotoxic T lymphocytes raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. Eur J Immunol (1995) 1.19

Hierarchy among multiple H-2b-restricted cytotoxic T-lymphocyte epitopes within simian virus 40 T antigen. J Virol (1995) 1.18

T cell competition for the antigen-presenting cell as a model for immunodominance in the cytotoxic T lymphocyte response against minor histocompatibility antigens. Eur J Immunol (1999) 1.17

In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol (2003) 1.14

In vivo CTL induction with point-substituted ovalbumin peptides: immunogenicity correlates with peptide-induced MHC class I stability. Vaccine (1995) 1.10

An endoplasmic reticulum-targeting signal sequence enhances the immunogenicity of an immunorecessive simian virus 40 large T antigen cytotoxic T-lymphocyte epitope. J Virol (1998) 1.09

Simian virus 40 large T antigen contains two independent activities that cooperate with a ras oncogene to transform rat embryo fibroblasts. J Virol (1995) 1.05

Crystal structures of murine MHC Class I H-2 D(b) and K(b) molecules in complex with CTL epitopes from influenza A virus: implications for TCR repertoire selection and immunodominance. J Mol Biol (2004) 1.00

Nondominant CD8 T cells are active players in the vaccine-induced antitumor immune response. J Immunol (2011) 0.99

Binding of viral antigens to major histocompatibility complex class I H-2Db molecules is controlled by dominant negative elements at peptide non-anchor residues. Implications for peptide selection and presentation. J Biol Chem (1996) 0.98

Peptide-MHC class II complex stability governs CD4 T cell clonal selection. J Immunol (2009) 0.96

Localization of an immunorecessive epitope on SV40 T antigen by H-2Db-restricted cytotoxic T-lymphocyte clones and a synthetic peptide. Virology (1989) 0.95

Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol (2005) 0.94

Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease. J Virol (2012) 0.91

Avoiding tolerance against prostatic antigens with subdominant peptide epitopes. J Immunother (2001) 0.91

Abortive activation of CD4 T cell responses during competitive priming in vivo. Proc Natl Acad Sci U S A (2009) 0.90

Control of advanced choroid plexus tumors in SV40 T antigen transgenic mice following priming of donor CD8(+) T lymphocytes by the endogenous tumor antigen. J Immunol (2001) 0.88

Cytotoxic T lymphocytes from HLA-A2.1 transgenic mice define a potential human epitope from simian virus 40 large T antigen. Cancer Res (2001) 0.88

Role of non-anchor residues of Db-restricted peptides in class I binding and TCR triggering. Mol Immunol (1996) 0.87

The H4b minor histocompatibility antigen is caused by a combination of genetically determined and posttranslational modifications. J Immunol (2003) 0.85

Db-binding peptides from influenza virus: effect of non-anchor residues on stability and immunodominance. Mol Immunol (1995) 0.84

Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol (2006) 0.83

In vivo expansion of the residual tumor antigen-specific CD8+ T lymphocytes that survive negative selection in simian virus 40 T-antigen-transgenic mice. J Virol (2004) 0.82

Effect of point mutations in the native simian virus 40 tumor antigen, and in synthetic peptides corresponding to the H-2Db-restricted epitopes, on antigen presentation and recognition by cytotoxic T lymphocyte clones. J Immunol (1992) 0.82

CD8+ T-cell cross-competition is governed by peptide-MHC class I stability. Eur J Immunol (2011) 0.81

Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. Eur J Immunol (2004) 0.81

Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology (2007) 0.78

Articles by these authors

Randomized controlled trial of oral glutathione supplementation on body stores of glutathione. Eur J Nutr (2014) 1.96

Immune defects in 28-kDa proteasome activator gamma-deficient mice. J Immunol (2004) 1.46

Another view of T cell antigen recognition: cooperative engagement of glycolipid antigens by Va14Ja18 natural T(iNKT) cell receptor [corrected]. J Immunol (2003) 1.38

In vivo ligation of CD40 enhances priming against the endogenous tumor antigen and promotes CD8+ T cell effector function in SV40 T antigen transgenic mice. J Immunol (2003) 1.14

An HLA-A2.1-transgenic rabbit model to study immunity to papillomavirus infection. J Immunol (2006) 1.09

TCR gene therapy of spontaneous prostate carcinoma requires in vivo T cell activation. J Immunol (2008) 1.08

The dual role of CD8+ T lymphocytes in the development of stress-induced herpes simplex encephalitis. J Neuroimmunol (2003) 0.98

Inefficient cross-presentation limits the CD8+ T cell response to a subdominant tumor antigen epitope. J Immunol (2005) 0.94

Regression of established hepatocellular carcinoma is induced by chemoimmunotherapy in an orthotopic murine model. Hepatology (2012) 0.93

Early immunization induces persistent tumor-infiltrating CD8+ T cells against an immunodominant epitope and promotes lifelong control of pancreatic tumor progression in SV40 tumor antigen transgenic mice. J Immunol (2006) 0.90

Anti-CD40 conditioning enhances the T(CD8) response to a highly tolerogenic epitope and subsequent immunotherapy of simian virus 40 T antigen-induced pancreatic tumors. J Immunol (2007) 0.88

Presentation of human T cell leukemia virus type 1 (HTLV-1) Tax protein by dendritic cells: the underlying mechanism of HTLV-1-associated neuroinflammatory disease. J Leukoc Biol (2009) 0.87

CD8+ T cells targeting a single immunodominant epitope are sufficient for elimination of established SV40 T antigen-induced brain tumors. J Immunol (2008) 0.86

Why Do CD8+ T Cells become Indifferent to Tumors: A Dynamic Modeling Approach. Front Physiol (2011) 0.83

Accumulation of CD8+ T cells in advanced-stage tumors and delay of disease progression following secondary immunization against an immunorecessive epitope. J Immunol (2006) 0.83

Effects of sleep loss on team decision making: motivational loss or motivational gain? Hum Factors (2007) 0.83

Durable complete responses off all treatment in patients with metastatic malignant melanoma after sequential immunotherapy followed by a finite course of BRAF inhibitor therapy. Cancer Biol Ther (2015) 0.82

CD8 T cells recruited early in mouse polyomavirus infection undergo exhaustion. J Immunol (2012) 0.81

An SV40 VP1-derived epitope recognized by CD8+ T cells is naturally processed and presented by HLA-A*0201 and cross-reactive with human polyomavirus determinants. Virology (2008) 0.81

The assembly of functional beta(2)-microglobulin-free MHC class I molecules that interact with peptides and CD8(+) T lymphocytes. Int Immunol (2002) 0.80

Unsuccessful high dose IL-2 therapy followed immediately by near continuous low dose temozolomide can result in rapid durable complete and near-complete remissions in metastatic melanoma. Cancer Biol Ther (2010) 0.79

Rapid accumulation of adoptively transferred CD8+ T cells at the tumor site is associated with long-term control of SV40 T antigen-induced tumors. Cancer Immunol Immunother (2007) 0.79

Combined anti-CD40 conditioning and well-timed immunization prolongs CD8+ T cell accumulation and control of established brain tumors. J Immunother (2008) 0.78

Using HLA-A2.1 Transgenic Rabbit Model to Screen and Characterize New HLA-A2.1 Restricted Epitope DNA Vaccines. J Vaccines Vaccin (2010) 0.78

Direct presentation regulates the magnitude of the CD8+ T cell response to cell-associated antigen through prolonged T cell proliferation. J Immunol (2010) 0.78

Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones. Virology (2007) 0.78

Anaplastic renal carcinoma expressing SV40 T antigen in a female TRAMP mouse. Comp Med (2013) 0.76

Protection from tumor recurrence following adoptive immunotherapy varies with host conditioning regimen despite initial regression of autochthonous murine brain tumors. Cancer Immunol Immunother (2014) 0.76

Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther (2010) 0.76

Propanil exposure induces delayed but sustained abrogation of cell-mediated immunity through direct interference with cytotoxic T-lymphocyte effectors. Environ Health Perspect (2006) 0.75

Hearing and performance during a 70-h exposure to noise simulating the space station environment. Aviat Space Environ Med (2004) 0.75